Images List Premium Download Classic

Fatty Liver

Fatty Liver-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Method for discriminating symptom of hepatic disease
Sumitomo Dainippon Pharma Co., Ltd.
April 12, 2018 - N°20180100867

Provided is a noninvasive method for determining the presence of a symptom of a hepatic disease such as nonalcoholic fatty liver disease with a higher diagnostic accuracy. A method for discriminate between nonalcoholic fatty liver (nafl) and nonalcoholic steatohepatitis (nash), the method comprising: (1) a step of measuring the quantities of marker molecules contained in blood collected from a subject; (2) a ...
Diagnostics and methods for treatment of non-alcoholic hepatic steatosis and hepatic steatohepatitis, and prevention of ...
Volant Holdings Gmbh
April 12, 2018 - N°20180099001

The present invention is directed to a system characterization of nash that combines modeling and biomarkers, enabling pharmaceutical compositions and methods of treatment that relate to the inhibition, resolution and/or prevention of non alcoholic fatty liver disease (nafld) and non alcoholic steatohepatitis (nash). Said conditions are liver related complications among the array of manifestations of metabolic syndromes, including type 2 ...
Methods for treating obesity and nonalcoholic fatty liver disease or nonalcoholic steatohepatitis using glucagon receptor ...
Remd Biotherapeutics, Inc.
March 22, 2018 - N°20180079820

The present disclosure relates to methods for treating or preventing obesity and/or nonalcoholic fatty liver diseases (naflds) and/or nonalcoholic steatohepatitis (nash) using a glucagon receptor blocking agent. In various embodiments, the present disclosure relates to methods for treating or preventing nafld/nash using antigen binding and antagonizing proteins, e. G., fully human antibodies, that specifically bind to and ...
Fatty Liver Patent Pack
Download + patent application PDFs
Fatty Liver Patent Applications
Download + Fatty Liver-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Fatty Liver-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Pharmaecutical composition containing silybin, ve and l-carnitine
Tasly Pharmaceutical Group Co., Ltd.
March 01, 2018 - N°20180055817

A pharmaceutical composition. The pharmaceutical composition is prepared from the following raw materials in parts by weight: 8. 75-60 parts of silybin, 15-65 parts of phospholipid, 25-200 parts of a pu'er tea extract, 6. 25-40 parts of vitamin e, and 8. 3-60 parts of l-carnitine. The composition can be used for treating non-alcoholic fatty liver diseases.
Therapeutics and methods of treating fatty liver disease
Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College
February 22, 2018 - N°20180051289

A method of treating a condition in a mammal comprising administering a pharmacologically effective amount of a therapeutic, wherein the therapeutic one of increases epha2 expression and supplements ephrin type-a receptor 2, and the condition is one of fatty liver disease, elevated plasma cholesterol level, and elevated plasma triglyceride level.
Compositions and methods for treating and preventing hyperlipidemia, fatty liver, atherosclerosis and other disorders associated ...
Vanderbilt University
February 22, 2018 - N°20180050083

The present invention relates to compositions and methods for treating diseases associated with dyslipidemia, including hypercholesterolemia, hypertriglyceridemia, steatohepatitis, atherosclerosis, obesity, hyperglycemia, metabolic syndrome, and related aspects of and conditions associated with metabolic syndrome. The compositions and methods disclosed herein are useful for regulating the lipid balance (lipid homeostasis) in a subject. Compositions and methods including a nuclear transport modifier may ...
Fatty Liver Patent Pack
Download + patent application PDFs
Fatty Liver Patent Applications
Download + Fatty Liver-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Fatty Liver-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Pharmaceutical composition containing silybin and ve
Tasly Modern Tcn Garden Co., Ltd.
February 22, 2018 - N°20180050015

A pharmaceutical composition is prepared from the following raw materials (in parts by weight): silybin (8. 75-60), phospholipid (15-65), a pu'er tea extract (25-200), and vitamin e (6. 25-40). The composition has the effect of treating non-alcoholic fatty liver diseases.
Pharmaceutical composition containing silybin
Tasly Pharmaceutical Group Co., Ltd.
February 15, 2018 - N°20180042893

A pharmaceutical composition for treating non-alcoholic fatty liver diseases consists of a silybin-phospholipid complex preparation and pu'er tea/tea product according to a weight ratio of 0. 5-2. 5:0. 3-10, wherein the silybin-phospholipid complex capsule preparation and the pu'er teat/tea product are separately packaged.
Pharmaceutical composition containing silibinin
Tasly Pharmaceutical Group Co., Ltd.
February 15, 2018 - N°20180042892

Disclosed is a pharmaceutical composition containing silibinin, which is prepared from the following bulk drugs by weight ratio: 8. 75-60 parts of silibinin, 15-65 parts of phospholipid, and 25-200 parts of pu'er tea extract. The drug has the function of treating non-alcoholic fatty liver.
Methods for treating metabolic disorders using fgf
Salk Institute For Biological Studies
February 08, 2018 - N°20180036377

The method provides methods and compositions for treating metabolic disorders such as impaired glucose tolerance, elevated blood glucose, insulin resistance, dyslipidemia, obesity, and fatty liver.
Methods and compositions for identifying non-alcoholic fatty liver disease
The Regents Of The University Of California
February 01, 2018 - N°20180031585

The disclosure provides methods for differentiating between non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. The method includes measuring eicosanoids and fatty acid levels in a biological sample.
Deuterated chenodeoxycholic acid derivative and pharmaceutical composition comprising compound thereof
Suzhou Zelgen Biopharmaceuticals Co., Ltd.
February 01, 2018 - N°20180030083

Disclosed are deuterated chenodeoxycholic acid derivatives and pharmaceutical compositions containing the deuterated chenodeoxycholic acid derivatives. In particular, disclosed is a deuterated chenodeoxycholic acid derivative of formula (i), or a crystal form, pharmaceutically acceptable salt, hydrate or solvate thereof, and a pharmaceutical composition containing the same. The deuterated chenodeoxycholic acid derivatives of formula (i) can be used to treat and/or ...
Use of interleukin-22 in the treatment of fatty liver disease
Generon (shanghai) Corporation Ltd.
February 01, 2018 - N°20180028614

The present invention relates to use of interleukin-22 (il-22) for treating fatty liver disease by decreasing the levels of transaminases. The use of il-22 in decreasing the levels of transaminases is also provided.
Fatty Liver Patent Pack
Download + patent application PDFs
Fatty Liver Patent Applications
Download + Fatty Liver-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Fatty Liver-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Drug for inhibiting adipose cell differentiation and insulin resistance
Beijing Protgen Ltd.
January 18, 2018 - N°20180015148

The present invention provides use of endostatin or a functional variant thereof in the preparation of a medicament for treating dietary obesity, non-alcoholic fatty liver disease, insulin resistance or glucose intolerance. In the embodiments of the present invention, the functional variant may be yh-16, mes, myh-16, m003, m007, mz101, or the like.
Pharmaceutical compositions for combination therapy
Intercept Pharmaceuticals, Inc.
January 11, 2018 - N°20180008616

The present invention relates to a pharmaceutical composition comprising a combination of an fxr agonist and at least one lipid lowering agent (e. G., ppar-alpha agonist, ppar-delta agonist, ppar-alpha and delta dual agonist, and/or statin). Also disclosed is use of the combination for the treatment or prevention of a fxr mediated disease or condition, such as primary biliary cirrhosis (...
Treatment for non-alcoholic fatty liver diseases
Dsm Ip Assets B.v.
January 04, 2018 - N°20180000775

The present invention relates to the use of mixtures of vitamin e and polyunsaturated fatty acids (pufas) as agents for the prevention, control and/or treatment of conditions associated with excessive fat accumulation in the liver which is not caused by alcohol abuse. This includes prevention, control and/or treatment of non-alcoholic steatosis in the liver—known as non-alcoholic ...
Biomarkers for fatty liver disease and methods using the same
Metabolon, Inc.
December 28, 2017 - N°20170370954

Biomarkers of nash, nafld, and fibrosis and methods for diagnosis (or aiding in the diagnosis) of nafld, nash and/or fibrosis are described herein. Additionally, methods of distinguishing between nafld and nash, methods of classifying the stage of fibrosis, methods of determining the severity of liver disease, methods of determining the severity of liver disease or fibrosis, and methods of ...
Ostreolysin, functionally related variant thereof, extract comprising ostreolysin and uses thereof
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.
December 28, 2017 - N°20170368133

Disclosed are methods for treating, preventing and alleviating obesity, fatty liver syndrome, diabetes, one or more metabolic syndrome conditions or complications and/or cancer comprising administering an effective amount of ostreolysin, its functionally related variant, or an extract or mushroom extract comprising the same to subjects in need thereof.
Grape seed products for nonalcoholic fatty liver disease and other uses
The United States Of America, As Represented By The Secretary Of Ariculture
December 28, 2017 - N°20170368128

Embodiments described herein provide for uses of grape products, such as chardonnay grape products and grape seed flour, for use in promoting a healthy liver, promoting healthy fat content in a liver, for treating or preventing nafld, and other embodiments and uses as described herein.
Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders
Genfit
December 28, 2017 - N°20170368007

The invention provides 1,3-diphenylprop-2-en-1-one derivatives and pharmaceutical compositions comprising the same for treating liver disorders, in particular those requiring the reduction of plasma level of biochemical markers such as aminotransferases. The 1,3-diphenylprop-2-en-1-one derivatives of general formula (i) have hepatoprotective properties and can be used in methods for treating liver disorders involving the pathological disruption, inflammation, degeneration, ...
Co-agonists of the glucagon and glp-1 receptors
Merck Sharp & Dohme Corp.
December 21, 2017 - N°20170360893

Described are peptide analogs of glucagon, which have been modified to be resistant to cleavage and inactivation by dipeptidyl peptidase iv (dpp-iv) and to increase in vivo half-life of the peptide analog while enabling the peptide analog to have relatively balanced agonist activity at the glucagon-like peptide 1 (glp-1) receptor and the glucagon (gcg) receptor, and the use of such glp-1 ...
Loading